

Supplements

S1 The CHADS2, CHA2DS2-VASc, and HAS-BLED scores in patients with VAF

	N	%
CHADS2 score	599	
0	133	22.2
1	225	37.6
2	114	19.0
3	80	13.4
4	29	4.8
5	16	2.7
6	1	0.2
7	1	0.2
CHA ₂ DS ₂ -VSC		
0	36	6.0
1	127	21.2
2	166	27.7
3	106	17.7
4	80	13.4
5	52	8.7
6	21	3.5
7	10	1.7
8	1	0.2

HAS_BLED

0	218	36.4
1	189	31.6
2	131	21.9
3	49	8.2
4	11	1.8
5	1	0.2

S2 The univariable analysis of the factors associated with under-anticoagulation in patients with NVAF

Characteristics	OAC (n =948)	Non OAC (n = 2614)	p-Value
Age (years), mean \pm SD	67.14 \pm 11.29	70.12 \pm 11.66	<0.001
Female, n (%)	409 (43.1)	1132 (43.3)	0.9313
Duration of AF (years), mean \pm SD	5.04 \pm 5.96	5.15 \pm 6.42	0.5908
Region, n, (%)			<0.001
Northeast	27 (2.8)	98 (3.7)	
East	543 (57.3)	1736 (66.4)	
West	143 (15.1)	337 (12.9)	
Middle	235 (24.8)	443 (16.9)	
Hospital level, n (%)			<0.001
Secondary	84 (8.9)	560 (21.4)	
Tertiary	864 (91.2)	2054 (78.5)	
Current smoker, n (%)	90 (9.6)	293 (11.3)	0.3014
BMI (kg/m ²), mean \pm SD	24.49 \pm 3.35	24.17 \pm 3.53	0.0114
SBP (mmHg), mean \pm SD	127.84 \pm 16.86	131.77 \pm 18.30	<0.001
DBP (mmHg), mean \pm SD	78.20 \pm 10.98	78.84 \pm 11.81	0.1274
Type of AF, n (%)			<0.001
New-onset	89 (9.4)	381 (14.6)	
Paroxysmal	293 (31.1)	964 (37.0)	

Persistent	332 (35.2)	740 (28.4)	
Permanent	229 (24.3)	523 (20.1)	
Cardiovascular disease, n (%)			
Coronary artery disease	225 (23.8)	1096 (42.3)	<0.001
Hypertension	565(59.6)	1634 (62.6)	0.1063
Diabetes mellitus	165 (17.4)	459 (17.6)	0.9175
Heart failure	281 (29.7)	954 (36.6)	<0.001
NYHA classification			<0.001
II	98(10.3%)	225(8.6%)	
III	127(13.4%)	450(17.3%)	
IV	41(4.3%)	246(9.4%)	
Peripheral artery disease	46 (4.9)	115 (4.4)	0.5642
Renal dysfunction	27 (2.8)	140 (5.4)	0.0010
Hepatic disease	31 (3.3)	108 (4.1)	0.2306
Dyslipidemia	234 (24.7)	538 (20.6)	0.0088
Thromboembolic events, n (%)			
Ischemic stroke	138 (14.6)	310 (11.9)	0.0342
TIA	31 (3.3)	73 (2.8)	0.4598
Non-CNS embolism	16 (1.7)	13 (0.5)	0.0011
Bleeding events			
GI bleeding	20(2.1)	54(2.1)	0.9354
ICH	19(2.0)	37(1.4)	0.2235

Antiarrhythmic treatment, n (%)			<0.001
Rhythm control	265 (28.0)	525 (20.1)	
Rate control	503 (53.1)	1396 (53.5)	
Both	113 (11.9)	257 (9.8)	

S3 The univariable analysis of the factors associated with under-anticoagulation in patients with VAF

Characteristics	OAC (n =345)	Non OAC (n = 254)	P
Age (years), mean \pm SD	60.03 \pm 11.6	64.59 \pm 11.48	<0.001
Female, n (%)	236 (68.4)	173 (68.1)	0.939
Duration of AF (years), mean \pm SD	8.75 \pm 9.02	8.15 \pm 9.12	0.4429
Region, n, (%)			0.0130
Northeast	5 (1.4)	8 (2.2)	
East	213 (61.7)	172 (67.7)	
West	67 (19.4)	36 (14.2)	
Middle	60 (17.4)	38 (15.0)	
Hospital level, n (%)			0.009
Secondary	44 (12.8)	54 (21.3)	
Tertiary	301 (87.2)	200 (78.7)	
Current smoker, n (%)	16 (4.7)	12 (4.7)	0.994
BMI (kg/m ²), mean \pm SD	22.55 \pm 3.20	22.97 \pm 3.65	0.052
SBP (mmHg), mean \pm SD	122.63 \pm 16.52	124.03 \pm 17.84	0.324
DBP (mmHg), mean \pm SD	74.16 \pm 10.51	76.56 \pm 11.79	0.011
Type of AF, n (%)			0.038
New-onset	19 (5.6)	22 (8.7)	
Paroxysmal	42 (12.3)	48 (19.0)	

Persistent	131 (38.3)	90 (36.6)	
Permanent	150 (43.9)	93 (36.8)	
Cardiovascular disease, n (%)			
Coronary artery disease	36 (10.4)	38 (15.1)	0.091
Hypertension	94 (27.2)	84 (32.3)	0.182
Diabetes mellitus	48 (13.9)	33 (13.0)	0.744
Heart failure	211 (61.5)	142 (56.1)	0.186
NYHA classification			<0.001
II	58(16.9%)	16(6.3%)	
III	103 30.0%)	65(25.7%)	
IV	43(12.5%)	58(22.9%)	
Peripheral artery disease	18 (5.2)	5 (2.0)	0.441
Renal dysfunction	11 (3.2)	8 (3.1)	0.979
Hepatic disease	16 (4.6)	13 (5.1)	0.787
Dyslipidemia	40 (11.6)	39 (15.4)	0.181
Thromboembolic events, n (%)			
Ischemic stroke	47 (13.6)	23 (9.1)	0.082
TIA	13 (3.8)	6 (2.4)	0.325
Non-CNS embolism	10 (2.9)	3 (1.2)	0.139
Bleeding events			
GI bleeding	5(1.4)	8(3.1)	0.161
ICH	9(2.6)	2(0.8)	0.129

others			
Antiarrhythmic treatment, n (%)			0.007
Rhythm control	29 (8.4)	35 (13.8)	
Rate control	265 (77.0)	166 (65.4)	
Both	23 (6.7)	17 (6.7)	